Hanmi Science Co., Ltd.

Hanmi Pharm. Co., Ltd.

Korea Institute of Science and Technology

Catholic University Industry Academic Cooperation Foundation

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Young Hee Jung

Maeng Sup Kim

Young Gil Ahn

Jung Beom Son

Seung Hyun Jung

Hwan Mook Kim

Hwan Geun Choi

Tae Bo Sim

Young Jin Ham

Ji Young Song

Seung Ah Jun

Dong-sik Park

Dong-wook Kim

Gwan Sun Lee

Jae Chul Lee

Eun Young Kim

Ji Yeon Song

Bum Woo Park

In Hwan Bae

Ji Sook Kim

Jae Yul Choi

Jung Mi Hah

Han Kyong Kim

Young Kil Chang

Mi Young Cha

Mi Kyoung Lee

Ho Seok Kim

Nam Du Kim

Mi Ra Kim

Se Young Kim

Eun Young Byun

Mi Young Ko

Hee Cheol Kim

Young-Gil Ahn

Tae Hun Song

Wha Ii Choi

Hae Kyoung Ju

Chang Gon Lee

Bo Im Choi

Kyu Hang Lee

Wha Il Choi

Eun Ju Jeon

In Ho Yang

Myoung Sil Ko

Mi Yon Shim

Kwang-Ok Lee

Keukchan Bang

Yun Jung Chae

Kyung Ik Lee

Dong-Wook Kim

Hwan Kim

The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-&#x3b2;, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Pyrazole derivative as ALK5 inhibitor and uses thereof

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

Bicyclic compound for modulating G protein-coupled receptors

Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Quinoline or quinazoline derivatives with apoptosis inducing activity on cells

The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient. 

Amide derivative for inhibiting the growth of cancer cells

Growing community of inventors

Seoul, South Korea

Young Hee Jung